psychedelic treatments traumarelated disorders use psychedelic substances either alone used conjunction psychotherapy treat traumarelated traumarelated disorders posttraumatic stress disorder ptsd lifetime prevalence around us however even though traumarelated disorders hinder everyday life individuals less patients meet criteria ptsd diagnosis receive proper psychotherapy effective treatment traumarelated disorders metaanalysis treatment outcomes shown patients completed treatment ptsd longer met diagnostic criteria seeking evidencebased psychotherapy treatment estimated drop addition psychotherapy pharmacotherapy medication option treating ptsd however research found pharmacotherapy effective although forms treatment effective many patients high dropout rates psychotherapy treatmentresistant forms ptsd led increased research possible forms treatment one form use psychedelics lysergic acid diethylamide lsd psilocybin researched used treatments united states america mental disorders early however research use psychedelics treatment halted passing controlled substance act comprehensive drug abuse prevention control even though research hindered many decades renewed interest use psychedelics help treatment traumarelated disorders many organizations one well known multidisciplinary association psychedelic studies mdma psilocybin given status breakthrough therapies us food drug administration fda allowed clinical trials substances use psychedelic treatments mental fda approved ketamine use treatment currently three common psychedelic drugs researched mdma psilocybin substance different rationales treatment various treatment methods mdma first synthesized merck co designed initially bloodclotting agent found psychotropic properties although drug found effective blood clotting medication later resynthesized chemist alexander shulgin drug grew popularity psychotropic properties ability facilitate alter emotional states mdma commonly known street name ecstasy currently mdma classified schedule drug united states meaning viewed accepted medical use high potential primary rationale behind use mdma conjunction psychotherapy mdma help facilitate talk therapy reducing fear anxiety around traumatic memories makes processing memories mdma shown increase emotional empathy compassion self others increase prosocial behaviors increase subjective ratings closeness trust others increase potential benefits mdma usage help therapist talk therapy address traumatic events suffered patients mdma also known decrease fear around memories increase fear extinction traumatic lastly mdma helps reduce activation amygdala associated increase fear increases activation frontal cortex associated better processing control retrieving mdmaassisted psychotherapy treatments start administration mdma orally initial doses ranging mg one two hours second dose half initial dose offered sessions patients encouraged alternate introspection periods talking usually two therapists accompany patient influence mdma help facilitate introspection encourage remembering processing traumatic events patients given time relax listen music help induce periods therapy sessions last hours usually end drugs effects patients return baseline patients monitored stay night clinic leave following three integration sessions patients discuss experience mdma session process emotions receives psychoeducation held morning shortly mdma session cases process mdma sessions followed integration sessions repeated three times usually month multiple trials mdmaassisted psychotherapy shown significantly reduce ptsd symptoms improvement symptoms continued months follow patients reporting quality life improvements addition traumarelated symptom psilocybin chemical commonly found variety mushrooms although used centuries native people central south america fully introduced united states commonly referred magic mushrooms compound psilocybin successfully synthesized roger heim albert hofmann longer requires mushrooms psilocybin cause sensory perception changes auditory visual illusions currently psilocybin classified schedule drug united main rationale behind using psilocybin combined psychotherapy psilocybin shown increase fear extinction around emotions increase emotional much like mdma effects psilocybin shown help therapists talk therapy psilocybin shown increasing emotional empathy creative thinking mindfulness insightfulness patients help therapist work client overcome also like mdma psilocybin shown decrease amygdala activation emotional treatments using psilocybin focused reducing depression anxiety common comorbid diagnoses traumarelated disorders share many similar symptoms ie anhedonia sleep disturbance negative cognitions feelings guilt psilocybin treatments start orally administering mg psilocybin much like session mdma psilocybinassisted psychotherapy sessions nondirective alternate periods allowing patient relax listen music look introspectively periods talking shortly psilocybin session usually following day integration followup psychotherapy session done patient discuss experience provide psychotherapy goal integration sessions help process emotions process traumatic event provide psychoeducation address concerns treatment two psychotherapy sessions follow next weeks three followup sessions second psilocybin session followed three integration weak evidence psilocybin may useful treating ketamine useful anesthetic widely used throughout first synthesized later approved use anesthetic ketamine dissociative psychedelic addition effects ketamine fastacting united states ketamine classified schedule iii meaning considered substantially safe used medical purposes pharmacist management main rationale behind use ketamineassisted psychotherapy recognition effective depressive symptomology major comorbid problem traumarelated disorders treating depression help treat trauma provide opportunities therapist address issues addition ketamine shown increase synaptic neuronal help remodel traumatic memories unlike mdma psilocybin treatments ketamine done independently psychotherapy treatments ketamine given patients either intravenously orally controlled doses settings ketamine given patients psychotherapy help induce state help facilitate therapeutic sometimes addition dose given session small controlled quantities may allowed patients take home sessions studies used ketamine addition psychotherapy showed effective reducing depression anxiety ptsd treatments used ketamine psychotherapy sessions shown associated decreased rates developing ptsd experiencing traumatic well reducing ptsd psychedelics controlled substances us concerns use treating mental health disorders including traumarelated disorders adverse effects addiction significant concerns people discussing psychedelics benefit treatment like substance introduced body always risk adverse reaction stigma around psychedelics within us nearly studies researching psychedelics treatment report adverse effects addiction risks metaanalysis research studies looking psychedelics use mental health treatment found studies reported least one participant mild adverse effect taking psychedelics however none situations required medical adverse effects range physical effects blood pressure changes muscle tension headaches vomiting cognitive impacts experiences panic fear confusion low even possible adverse effects events tolerated well patients drugs seem good safety profile patients clinicians saw longterm benefits psychedelics treatment outweigh acute aversive primary concern addiction also monitored research found psychedelics used treatment low drug dependency rates participants reporting drug addictions substances used httpsenwikipediaorgwikipsychedelictreatmentsfortraumarelateddisorders